PubRank

Tomohiko Urano

Author PubWeight™ 47.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007 8.87
2 Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009 5.12
3 Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J 2013 1.48
4 Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 2009 1.20
5 TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol Endocrinol 2012 1.15
6 Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res 2005 1.00
7 A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15. Biochem Biophys Res Commun 2006 0.99
8 Association of a single-nucleotide variation (A1330V) in the low-density lipoprotein receptor-related protein 5 gene (LRP5) with bone mineral density in adult Japanese women. Bone 2007 0.99
9 Estrogen-responsive RING finger protein controls breast cancer growth. J Steroid Biochem Mol Biol 2003 0.98
10 Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 2009 0.98
11 14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival. Clin Cancer Res 2012 0.97
12 Increased expression of estrogen-related receptor alpha (ERRalpha) is a negative prognostic predictor in human prostate cancer. Int J Cancer 2007 0.96
13 Vitamin K2 suppresses proliferation and motility of hepatocellular carcinoma cells by activating steroid and xenobiotic receptor. Endocr J 2009 0.95
14 FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 2008 0.93
15 Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer 2011 0.93
16 Common variants in a novel gene, FONG on chromosome 2q33.1 confer risk of osteoporosis in Japanese. PLoS One 2011 0.92
17 alpha-Synuclein stimulates differentiation of osteosarcoma cells: relevance to down-regulation of proteasome activity. J Biol Chem 2006 0.91
18 EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer. Int J Cancer 2003 0.89
19 Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol 2014 0.88
20 ARFGAP3, an androgen target gene, promotes prostate cancer cell proliferation and migration. Int J Cancer 2011 0.86
21 The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab 2008 0.85
22 Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer. Prostate 2007 0.84
23 Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer. Cancer Sci 2011 0.84
24 Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res 2005 0.83
25 Glucocorticoid-induced gene tripartite motif-containing 63 (TRIM63) promotes differentiation of osteoblastic cells. Endocr J 2010 0.83
26 Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients. J Bone Miner Metab 2009 0.83
27 A1330V polymorphism of low-density lipoprotein receptor-related protein 5 gene and self-reported incident fractures in Japanese female patients with rheumatoid arthritis. Mod Rheumatol 2008 0.81
28 Clinical significance of amyloid precursor protein in patients with testicular germ cell tumor. Adv Urol 2013 0.81
29 Estrogen activates cyclin-dependent kinases 4 and 6 through induction of cyclin D in rat primary osteoblasts. Biochem Biophys Res Commun 2002 0.81
30 Terf/TRIM17 stimulates degradation of kinetochore protein ZWINT and regulates cell proliferation. J Biochem 2011 0.80
31 Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer. Cancer Sci 2009 0.80
32 Pregnane X receptor knockout mice display osteopenia with reduced bone formation and enhanced bone resorption. J Endocrinol 2010 0.80
33 Induction of anti-metallothionein antibody and mercury treatment decreases bone mineral density in mice. Toxicol Appl Pharmacol 2002 0.79
34 Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth. Cancer Sci 2014 0.78
35 PROX1 suppresses vitamin K-induced transcriptional activity of Steroid and Xenobiotic Receptor. Genes Cells 2011 0.78
36 Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 2009 0.78
37 EBAG9 is a tumor-promoting and prognostic factor for bladder cancer. Int J Cancer 2009 0.77
38 Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan. J Bone Miner Metab 2014 0.77
39 Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer. Int J Urol 2009 0.77
40 Augmentation of immune cell activity against tumor cells by Rauwolfia radix. J Ethnopharmacol 2002 0.76
41 Corrigendum: TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun 2015 0.76
42 The progesterone-responsive gene 14-3-3τ enhances the transcriptional activity of progesterone receptor in uterine cells. J Mol Endocrinol 2012 0.75
43 [Responsiveness to hormones in aged osteoblasts]. Nihon Ronen Igakkai Zasshi 2003 0.75
44 [The role of estrogen in the regulation of blood vessel function]. Nihon Rinsho 2005 0.75
45 Efp as a new molecular target for breast cancer therapy. Anticancer Drugs 2003 0.75
46 [Molecular mechanism tissue-specific actions of selective estrogen receptor modulators]. Nihon Ronen Igakkai Zasshi 2006 0.75